抗白细胞介素6受体抗体托珠单抗可降低多中心Castleman病患者的血清铁调素水平。
Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
作者信息
Kawabata Hiroshi, Tomosugi Naohisa, Kanda Junya, Tanaka Yasuhiro, Yoshizaki Kazuyuki, Uchiyama Takashi
出版信息
Haematologica. 2007 Jun;92(6):857-8. doi: 10.3324/haematol.10794.
PMID:17550864
Abstract
We report two cases of multicentric Castleman's disease (MCD) whose serum hepcidin levels were rapidly down-regulated by administration of tocilizumab, an anti- interleukin 6 (IL-6) receptor antibody. Our results indicate that IL-6-induced hepcidin over-production may be involved in the pathophysiology of microcytic anemia commonly observed in this disease.
摘要
我们报告了两例多中心Castleman病（MCD）患者，其血清铁调素水平通过使用抗白细胞介素6（IL-6）受体抗体托珠单抗而迅速下调。我们的结果表明，IL-6诱导的铁调素过度产生可能参与了该疾病中常见的小细胞贫血的病理生理过程。
Zotero 插件